SRX Global Provides Update on Engineered T-Cell Strategy and Pending CERo Therapeutics Acquisition
SRX Global commented on recent industry activity in engineered T-cell therapies following a Pfizer licensing deal and provided an update on its pending acquisition of CERo Therapeutics.